Gradalis announces positive results from phase 2b VITAL trial of Vigil to treat patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer: Dallas Friday, January 16, ...
Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...
Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...
Pancreatic ductal adenocarcinoma (PDAC) is the most lethal form of pancreas cancer. It's also the most common form of the ...
An alternative splicing regulator previously implicated in calcium signaling in the heart ensures cell-type-specific mRNA processing of long neuronal mRNAs in the mouse brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback